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Upper tract urothelial carcinomas are tumors derived from urothelium along the urinary tract. Currently,
there are no reliable biomarkers for their diagnosis or for prediction of tumor progression outcomes. It
has a high incidence in Taiwanese populations at speciﬁc locations with exposure histories, and occurs
relatively more frequent in the ureter than in the pyelocaliceal cavities. Radical nephroureterectomy with
bladder cuff excision is the gold standard treatment for adequate local tumor control and better long-
term survival. Despite optimal surgical treatment, the patient outcomes are still not satisfactory. An
improved understanding of the biomolecular predictors is urgently needed to plan neoadjuvant/adjuvant
therapy and proper follow-up strategies. In this study, a literature search was carried out through the
PubMed database using the key words “upper tract urothelial carcinoma,” “prognostic factors,” and
“outcome” from January 1985 to August 2015. The results showed that several preoperative clinical
characteristics (such as chronic kidney disease, female sex, synchronous urothelial carcinoma of the
bladder, and tumor location) and molecular markers (such as glutathione S-transferase, p53 protein,
cyclooxygenase-2, TG-interacting factor, nuclear factor-kB, osteopontin, and hypoxia-inducible factor-1a)
could serve as candidate biomarkers for the early detection of progression to upper tract urothelial
carcinomas. Additional investigations of these results are required to resolve the gene combinations
precisely and personalize the management of upper tract urothelial carcinomas.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Upper tract urothelial carcinomas (UTUC) are tumors derived
from the urothelium along the urinary tract and account for only 5%
of urinary tract carcinomas.1 The incidence of pyelocaliceal tumors
has been reported to be about three times as common as ureteral
tumors.2 It has been described as having a high incidence in
Taiwanese populations at designated locations with speciﬁc expo-
sure histories.3 Unlike in a previous report, in these populations itd, Kaohsiung, 807, Taiwan.
).
ociation. Published by Elsevier Taoccurs more frequently in the ureter than in the pyelocaliceal
cavities, at a ratio of 2:1.2 Regardless of the tumor location in the
upper urinary tract, radical nephroureterectomy (RNU) with
bladder cuff excision is the gold standard treatment for adequate
local tumor control and better long-term survival owing to a high
recurrence rate in the remaining ureter. Despite optimal surgical
treatment, the 5-year cancer-speciﬁc mortality rates remain rela-
tive high among different studies.4,5
To date, the prognostic risk factors of tumor recurrence and
survival are still unclear. Therefore, an improved understanding of
biomolecular predictors is urgently needed to plan neoadjuvant/
adjuvant therapy and proper follow-up strategies. Several preop-
erative clinical parameters, including chronic kidney disease,3,6,7
female sex,8e10 synchronous bladder tumor, and hematuria7 have
been investigated as potential prognostic factors for outcomes in
UTUC patients. The purpose of this mini-review was to investigateiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
T.-M. Chien et al. / Urological Science 26 (2015) 230e234 231the previous reports regarding the signiﬁcant prognosticators of
UTUC on disease progression and survival.
2. Materials and methods
The PubMed databasewas searched for related articles using the
keywords “upper tract urothelial carcinoma,” “prognostic factors,”
and “outcome” from January 1985 to August 2015. Only articles in
English studying human participants were included in the current
literature review. Articles related to the keywordswere additionally
collected in this study. In total, 928 articles were identiﬁed and 31
articles were included in thismini-review. Because of the scarcity of
prospective randomized data, articles were selected for this review
using the following criteria: clinically useful predictive factors,
operation techniques, long-term clinical outcomes, large sample
size, and thorough statistical analysis.
3. Results
3.1. Clinicopathological characteristics
3.1.1. Chronic kidney disease
Whether chronic kidney disease (CKD) is a risk factor for bladder
recurrence and mortality for UTUC and urothelial carcinoma (UC)
treated by means of RNU was retrospectively reported by Chung
et al. in an 150 patient cohort.6 The CKD severity was presented as
an estimated glomerular ﬁltration rate calculated using the Modi-
ﬁcation of Diet in Renal Disease Study equation. They demonstrated
that in patients with earlier CKD and CKD stage 5 compared with
patients without CKD, the risks of bladder recurrence were much
higher (HR 2.43, p ¼ 0.05 and HR 3.95, p < 0.01, respectively). They
also showed a signiﬁcantly increased rate of bladder recurrence if
ureteral involvement of the primary tumor was present (HR 1.97,
p ¼ 0.02). Though CKD was correlated to the bladder recurrence
rate, the risk of death was not greater compared to those without
CKD. They concluded the CKD stage and ureteral involvement of the
primary tumor (especially in the lower ureter) were associated
with a greater risk of bladder recurrence but did not inﬂuence
survival.
Li et al.3 demonstrated that in renal insufﬁciency patients, 41.2%
developed bladder recurrence (compared to 29.7% bladder recur-
rence in patients with normal renal function) in a 260 UTUC patient
cohort.3 Similar to previous results, renal function was not related
to cancer-speciﬁc survival. Therefore, CKD is considered to affect
the risk of bladder recurrence but is not a predictor for cancer-
speciﬁc survival.
3.1.2. Sex
A multiple registries report that analyzed 4840 patients who
underwent RNU showed that women UTUC patients had more pT3
(43.1% vs. 39%; P ¼ 0.02) and grade III/IV (63.8% vs. 59.8%; P ¼ 0.04)
tumors.9 Therefore, women are more likely to have pT3 UTUC (HR
1.15, P ¼ 0.03). However, multivariable competing-risks regression
analysis showed no difference in survival rate by sex (HR 1.07,
P ¼ 0.4). They concluded that women are more likely to have more
advanced pathologic T stage and higher tumor grade when treated
with RNU. Sex did not inﬂuence cancer-speciﬁc survival.
The incidence of UTUC is slightly higher in Taiwanese women
than in men, as ﬁrst reported by Chou et al.10 Women had a
signiﬁcantly higher rate of contralateral tumor recurrence than
men after RNU during follow-up.8 There were no differences in the
rate of bladder recurrence, local recurrence, distant metastasis,
disease progression, or cancer-speciﬁc survival. Therefore, sex is
not considered to affect survival, but is correlated with contralat-
eral recurrence.Li at el. reported men had a higher risk of bladder recurrence,
especially with renal insufﬁciency, as compared to women with
normal renal function.3 These ﬁndings suggest that surveillance of
the contralateral kidney should be performed more carefully in
women, andmenwith renal insufﬁciency should havemore regular
cystoscopic follow-up after the initial RNU.
3.1.3. Previous/synchronous bladder tumor
A multi-center analysis in Japan11 showed a previous or coex-
istent bladder tumor was an independent risk factor for overall
survival in 1003 patients treated with RNU (HR 1.25, p ¼ 0.04). Li
et al. further evaluated the outcomes of patients with primary
ureteral urothelial carcinoma who underwent RNU. Patients with a
history of bladder tumor were excluded from the analysis.7 They
demonstrated that in patients with synchronous bladder tumors,
the initial behaviors of the ureteral tumors are more frequent
involved in inﬁltrating the muscle layer and deeper tissues, causing
obstructive uropathy. Therefore, macroscopic hematuria cannot be
seen at the initial presentation. Hematuria occurs only with su-
perﬁcial bladder tumors developing deep inside the bladder.
Delayed diagnosis may be the reason for advanced tumor staging.
In addition, a higher bladder recurrence rate was also noted in this
setting (p ¼ 0.036).
Based on these ﬁndings, for patients with synchronous bladder
tumors, a full course of intravesical therapy should be performed
with close follow-up of the clinical outcome. In conclusion, the
presence of a previous bladder tumor or synchronous bladder tu-
mor should always be treated with caution due to its high
aggressiveness.
3.1.4. Tumor location
A multicenter report from France using a 609 patient database
showed ureteral, synchronous ureteral and renal pelvic tumors had
a worse prognosis than tumors located in the renal pelvic alone.12
The 5-yr cancer-speciﬁc survival probability was 86.8% for renal
pelvic tumors, 68.9% for ureteral tumors, and 56.8% for synchro-
nous ureteral and renal pelvic tumors (p < 0.001).
A recent report from China also demonstrated ureteral tumors
weremore likely to presentwith advanced tumor stages (p < 0.001)
compared to renal pelvic tumors.13 This may be due partially to that
ureteral tumors are more likely to have hydronephrosis and less
likely to have hematuria, hence the conclusive diagnosis delayed.
Ureteral tumors showed a shorter 5-yr progression free survival
than renal pelvic tumors (68.7% vs. 54.2%, p ¼ 0.02).
On the contrary, studies from Taiwan3,7,8 did not conﬁrm the
independent prognostic impact of tumor location on survival,
ﬁnding the same overall survival and cancer-speciﬁc survival esti-
mates for renal pelvic cancer, ureteral cancer, and synchronous
ureteral and bladder tumors. To conclude, the current studies did
not conﬁrm a deﬁnite conclusion regarding the impact of tumor
location on the prognosis of UTUC. Further multicenter prospective
studies are needed to conﬁrm and clarify the results.
3.2. Surgical factors
3.2.1. Types of surgery
Open RNU with bladder cuff excision remains the gold standard
treatment of UTUC regardless of the tumor location in the urinary
tract.14 The safety of laparoscopic RNU has now been demonstrated
with advantages of lower blood loss, shorter hospital stays, and
more tolerable wound pain compared to the open procedure.
Oncologic outcomes after laparoscopic and open RNU tend to be
equivalent.3,7,11,14 A single center randomized study showed the
operative times were comparable, while mean blood loss andmean
time to discharge were signiﬁcantly lower in the laparoscopic
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grade tumors, the prognosis was signiﬁcantly different between the
two surgical procedures.15 Therefore, open RNU is still beneﬁcial for
locally advanced (pT3) and high-grade tumors compared to the
laparoscopic approach for both cancer-speciﬁc survival (p ¼ 0.039
and p ¼ 0.078, respectively) and metastasis free survival (p ¼ 0.004
and p ¼ 0.014, respectively). At our institution, RNU is performed
either openly or laparoscopically, as chosen by the operating sur-
geons, and they show almost the same oncological outcomes on
follow-up.3,7
3.2.2. Bladder cuff management
Li et al. included a 301 patient cohort comparing three different
methods of managing the bladder cuff-intravesical incision, extra-
vesical incision, and transurethral incision. Bladder recurrence
developed in 23.5%, 24%, and 17.6%, respectively (p ¼ 0.485); local
retroperitoneal recurrence in 7.4%, 7.8%, and 5.5% (p ¼ 0.798);
contralateral recurrence in 4.9%, 3.9%, and 2.2% (p ¼ 0.632); and
distant metastasis in 7.4%, 10%, and 5.5% (p ¼ 0.564).16 Among the
three groups, there were no differences in cancer speciﬁc survival
rate or recurrence free survival rate.
They also demonstrated that laparoscopic RNU and the choice
among three different methods for managing the distal ureter did
not affect the clinical outcome. In conclusion, RNU with bladder
cuff excision has to be considered the gold standard treatment of
UTUC regardless of the tumor location and stage. Although lapa-
roscopic approaches have been described, further advanced or
large studies should be performed to conﬁrm the results.
3.3. Molecular markers
3.3.1. p53
Rey el al. ﬁrst assessed the role of p53 on the cell cycle and tu-
mor progression to evaluate its value in predicting the long-term
survival of patients with UTUC.17 They reported an 83 patient
cohort, showing that patients with low p53 expression (<30% of
stained nuclei) had a better survival rate (88%) than those having
high (>30%) p53 expression (65%) (p < 0.02). High-grade tumors
and inﬁltrating tumors also showed statistical signiﬁcant higher
levels of p53 expression (p < 0.02 and p < 0.04, respectively). They
also demonstrated that p53 immunostaining can be used to
distinguish low-risk patients in the theoretically unfavorable high-
grade, high-stage group.
A report from Taiwan (n ¼ 112) revealed that high p53
expression was signiﬁcantly correlated with poor progression-
free survival and cancer-speciﬁc survival (p ¼ 0.025 and
p ¼ 0.021, respectively).18 Cox regression analysis demonstrated
overexpression of p53 was a prognostic factor for shorter
progression-free (HR ¼ 3.74, p ¼ 0.025) and cancer-speciﬁc
(HR ¼ 5.87, p ¼ 0.030) survival. To conclude, though current in-
formation shown that to evaluate the p53 immunohistochemical
staining in surgical specimen is beneﬁcial to identify risky pa-
tients, further studies are necessary to investigate the role of p53
in the carcinogenesis of UTUC and a clinically useful threshold of
the p53 value.
3.3.2. Glutathione S-transferase
Glutathione S-transferase (GST) is an important enzyme for
detoxifying environmental substances and carcinogenic com-
pounds. The high incidence with designated locations and expo-
sure histories were reported in Taiwanese3. A study reported by
Matic el al. identiﬁed threemajor cytosolic GSTclasses, GSTM, GSTP,
and GSTT, that are expressed in UTUCs.19 Expression of all of the
GSTs tends to increase during cancer progression. This ﬁnding is
similar to that observed in UCB, revealing the same alteration of theGST phenotype during tumorigenesis. Chen el al.20 showed GSTP1
was signiﬁcantly higher in UTUCs compared to normal urothelial
tissues in 46 Taiwanese patients (p < 0.001). Overexpression of
GSTP1 was also noted in high-grade tumors and invasive stage
tumors compared to that in normal urothelial tissues (p < 0.001).
Compared to superﬁcial UTUCs, invasive tumors showed a positive
correlation to GSTT1 expression (OR: 1.29, p ¼ 0.049). They
concluded GSTP1 overexpression is present in UTUC patients, and
GSTT1 is elevated in invasive tumors.3.3.3. Cyclooxygenase-2
Shirahama et al. reported the clinical signiﬁcance of
cyclooxygenase-2 (COX-2) expression with respect to clinicopath-
ologic ﬁndings and patient survival in urothelial carcinoma of the
human urinary bladder.21 They performed immunohistochemistry
on tumor tissues collected from 108 patients who underwent
radical cystectomy. They reported COX-2 expressionwas associated
with local invasion (p ¼ 0.047) but was not related to disease
prognosis (p ¼ 0.16).
Ke et al. examined the relationship between COX-2 expression
in tumor and stromal tissues and prognosis in Taiwanese UTUC
patients who underwent RNU.22 Interestingly, they conﬁrmed that
positive COX-2 expression can be detected not only in tumor cells
but also in stromal cells previous reported by Kang et al.23 For
patients with positive COX-2 expression, the cancer stage was
positively associated with cancer-speciﬁc survival (p ¼ 0.0109)
and cancer recurrence (p¼ 0.0235). However, COX-2 expression in
the tumor cells was not related to either cancer-speciﬁc survival or
recurrence-free survival. In conclusion, COX-2 expression in
stromal cells could be a prognostic factor for poor clinical
outcomes.3.3.4. TG-interacting Factor
TG-interacting factor (TGIF), a transcriptional co-repressor that
regulates TGF-b signaling, is related to various types of human
cancer. Huang et al. found that cellular migration activity, reactive
oxygen species production, AKTS473 phosphorylation, TGIF, and
p67phox expression were signiﬁcant elevated in invasive T24 cells
as compared to noninvasive RT4 cells. In addition, cellular migra-
tion/invasion ability was much higher in RT4 cells that overex-
pressed TGIF.24 The mechanisms involved are thought to include
NADPH oxidase 2 (Nox2)/p67phox complex activation, reactive
oxygen species production, and AKTS473 phosphorylation. Knock-
ing down TGIF or p67phox suppressed the migration/invasion
ability of T24 cells. They concluded that the cellular migration/in-
vasion ability of UC is mediated by the PI3K/AKT signaling pathway
leading to TGIF-induced Nox2/p67phox complex activation and the
resultant superoxide production, which reinforces PI3K/AKT
signaling.
Yeh et al. performed an analysis of 168 human UTUC specimens
to identify the relationship between TGIF in the nuclei of tumor
tissues and prognosis.25 In positive TGIF patients, the 5-year
progression-free survival and cancer-speciﬁc survival rates were
52.0% and 58.5%, respectively, compared with 74.1% and 86.5% for
TGIF negative patients. The prognostic effect of TGIF for UTUC was
ﬁrst reported by analyzing a Taiwanese UTUC cohort. Further
mechanistic studies showed that TGIF promotes the cellular
migration/invasion and proliferation of UTUC cells via the PI3K/AKT
pathway. They also demonstrated that altered p21 expression was
related to poor UTUC prognosis after surgical intervention. When
combining the alterations of TGIF and p21, the clinical outcomes
were not favorable. They concluded that assessment of TGIF may
provide more therapeutic and prognostic information for post-
operative follow-up plans.
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The transcription factor nuclear factorekB (NF-kB) can be
stimulated by carcinogens, inﬂammatory agents, and tumor pro-
moters. It is reported26 to be found activated in advanced human
bladder urothelial cells, and its inhibitors can induce apoptosis and
downregulate related gene products in human cell lines. Yeh et al.
showed that 61.1% of patients with UTUC overexpressed cyto-
plasmic NF-kB, and 26.7% of patients exhibited nuclear immuno-
reactivity of NF-kB.27 They identiﬁed a link between NF-kB
expression and UTUC prognosis. The expression of NF-kB was
signiﬁcantly elevated in UTUC cells compared to normal urothe-
lium, suggesting the malignant nature of the transformation.
Additionally, the nuclear staining of NF-kB was seen due to nuclear
translocation, which plays an important role for transcriptional
activation. On multivariate analysis, both disease-free survival (HR
2.87, p ¼ 0.0025) and overall survival (HR 2.24, p ¼ 0.0037) were
associated with NF-kB positive ﬁndings. The results demonstrate
nuclear staining of NF-kB correlates with survival and is indepen-
dently predictive of a poor clinical outcome in patients with UTUC.
NF-kB may be the next promising therapeutic target in selected
patients with UTUC.
3.3.6. Hypoxia-inducible factor-1
Tissue oxygenation is crucial for tumor growth. When tumors
grow larger, the production of newly generated blood vessels
through the angiogenesis process is triggered by hypoxic tumor
cells. Hypoxia-inducible factor-1 (HIF-1a) protein, which is found to
be elevated in hypoxia tissue, was reported during the carcino-
genesis and progression of UTUC in 2005. Nakanishi et al. showed
over half of the UTUC patients were found to have positive
expression of HIF-1a protein, and the protein was within the nu-
cleus in tumor cells. Positive HIF-1a expression was also related to
the tumor grade, tumor growth pattern, and p53 oncoprotein
expression. Both overall and disease-free survival rates were
signiﬁcantly correlated to HIF-1a protein expression.28 Ke et al.
further subdivided the patients with positive HIF-1a expression
into low and high groups according to their staining scores while
analyzing a 98 patient cohort.29 Tumor HIF-1a expression was
statistically correlated with tumor T stage (p < 0.001), N stage
(p < 0.001) and histological grade (p ¼ 0.004). Tumor necrosis was
associated with high tumor T stage (p < 0.001), N stage (p ¼ 0.002)
and histological grade (p < 0.001). Positive HIF-1a expression was
not always leading to necrosis due to its early expression after
tissue ischemia. A higher HIF-1a score was predictive of cancer-
speciﬁc survival (HR 2.23, p ¼ 0.004) and tumor recurrence (HR
1.58, p ¼ 0.036). In conclusion, high-expressing HIF-1a patients
may need more aggressive therapy and close post-operative
monitoring.
3.3.7. Osteopontin
Osteopontin (OPN), an adhesive glycoprotein, is not only an
immobilized extracellular matrix molecule but also a secreted
protein that can be measured in plasma or serum. Clinical studies
have demonstrated that elevated OPN level is correlated with
tumorigenesis, progression, and metastasis in many human tu-
mors. Ang et al. demonstrated that plasma OPN levels were higher
in patients with active bladder UC than in controls (p ¼ 0.035) by
analyzing a cohort of 72 consecutive patients with bladder UC.30
Plasma OPN levels were not signiﬁcantly different between the
active and inactive bladder UC patients, but were higher in patients
with metastases than in patients with active, clinically organ-
conﬁned bladder UC (p ¼ 0.021).
High tissue OPN expression in UTUC patients showed a strong
correlation with shorter cancer speciﬁc survival (RR 3.04, p ¼ 0.01)
by analyzing a patient cohort of 110 Taiwanese, even after adjustingfor T stage, N stage, and grade in multivariate analysis.31 They
showed that OPN expression was an independent prognostic factor
to predict cancer speciﬁc survival after surgery in patients with
UTUC. However, tissue OPN expression was not predictive of
recurrence-free survival (RR 0.9, p¼ 0.73). OPN overexpressionwas
also noted to be more common in women and ureter cancer. They
concluded higher tissue OPN expression may provide urologists
with a potential marker to screen for patients who need more
aggressive treatment.
4. Conclusion
The discovery of preoperative, perioperative, and post-
operative factors in important pathways in UTUC occurrence and
mechanism of formation and recurrence could serve as candidate
biomarkers for the early prediction of progression and survival.
These ﬁndings have clinical implications because they may play
an important role in predicting outcomes after RNU. Serum and
tissue molecule markers have the potential to improve the clinical
prediction of invasiveness, recurrence, and survival, and their
further study and development is urgently awaited. Advanced
investigation of these results is required to decipher the mecha-
nisms precisely and personalize the management of UTUC. There
are some limitations of this mini-review; ﬁrst, we could not
include all of the opinions from articles acquisitioned especially
those from Taiwan and second, bias arising from selection process
is also presented, thirdly, some of the novel molecular markers
with translational potential do not include. Prospective studies
validating the role of current factors and discovering new mo-
lecular markers to generate nomogram to select the groups of
patients at risk of progression are needed to help clinicians in the
decision-making process.
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